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Abstract
Introduction: Radioactive iodine (RAI) therapy may induce or worsen orbitopathy (GO) in Graves’ disease (GD). The aim of this study 
was a prospective assessment of the risk of GO exacerbation in a GD patients cohort submitted to RAI therapy for hyperthyroidism.
Material and methods: 208 consecutive GD patients treated with 131I in 2007 were enrolled. The analysis was performed on 156 patients 
strictly monitored for one year. Glucocorticosteroid (GCS) prophylaxis was administered if GO symptoms or GO history were present, 
and in cases of tobacco smokers even without GO symptoms. Clinical and biochemical evaluation at one, three, six, and 12 months after 
therapy was performed in the whole group, then at 24 months in 138 patients.
Results: There was no severe GO progression in patients without GO symptoms at the time of RAI treatment. The risk of severe GO 
worsening for preexisting GO patients (demanding systemic GCS administration) during the 12-month follow-up after RAI therapy 
was 10%. 12 and 24 months after 131I administration, stable improvement compared to the initial GO status had been achieved in most 
(98–96%) patients.
Conclusions: 
1. In patients with mild GO, the risk of severe GO worsening after RAI therapy is acceptable, as long as RAI therapy is applied with GCS cover.
2. In patients without GO symptoms at the time of RAI therapy but with a history of GO and with subclinical GO diagnosed by MRI only, 
the risk of severe progression is minimal.
3. Distant outcomes of RAI treatment confirmed its safety in GO patients. (Endokrynol Pol 2014; 65 (1): 40–45)
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Streszczenie
Wstęp: Leczenie jodem promieniotwórczym (131I) może indukować lub nasilać objawy orbitopatii u pacjentów z rozpoznaniem choro-
by Graves-Basedowa (CHGB). Celem pracy była prospektywna ocena ryzyka zaostrzenia orbitopatii w grupie chorych leczonych 131I 
z powodu nadczynności tarczycy.
Materiał i metody: Do badania włączono 208 kolejnych pacjentów z rozpoznaniem CHGB leczonych 131I w 2007. Do analizy włączono 
156 chorych ściśle monitorowanych przez rok. Osłona glikokortykoidowa (GCS) była stosowana w przypadku występowania objawów 
orbitopatii, dodatniego wywiadu w kierunku orbitopatii i u palaczy tytoniu, także bez objawów orbitopatii. Kliniczna i biochemiczna 
ocena była przeprowadzona w całej grupie 1, 3, 6 i 12 miesięcy po leczeniu 131I i u 138 chorych po 24 miesiącach. 
Wyniki: Nie obserwowano poważnego zaostrzenia orbitopatii u chorych bez objawów GO w chwili leczenia 131I. Ryzyko istotnej progresji 
orbitopatii (wymagającej stosowania GKS systemowych) w ciągu 12 miesięcznej obserwacji wynosiło u chorych z wyjściowymi objawami 
orbitopatii 10%. U większości chorych 12 i 24 miesiące po leczeniu 131I poprawa orbitopatii w porównaniu ze stanem wyjściowym była trwała.
Wnioski: 
1. Ryzyko istotnej progresji objawów po leczeniu 131I u chorych z orbitopatią o umiarkowanym nasileniu jest akceptowalne, 
2. Ryzyko progresji orbitopatii u chorych bez objawów w chwili leczenia 131I, ale z dodatnim wywiadem w kierunku orbitopatii i z sub-
klinicznymi objawami (obecnymi tylko w badaniu NMR) jest minimalne.
3. Odległa ocena potwierdza bezpieczeństwo terapii radiojodem u chorych z orbitopatią. (Endokrynol Pol 2014; 65 (1): 40–45)
Słowa kluczowe: orbitopatią Gravesa; liczenie 131I; profilaktyka glikokortykosteroidowa
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Introduction
Radioiodine (RAI) therapy is a radical method allowing 
the achievement of a permanent cure for hyperthyroid-
ism. It is generally the treatment of choice in cases of 
recurrent hyperthyroidism in the course of Graves’ 
disease (GD). It is also often used as the first-line treat-
ment for GD hyperthyroidism [1, 2].
RAI is an effective and safe treatment method of 
GD hyperthyroidism. However, in patients showing 
symptoms of Graves’ orbitopathy (GO), this therapy 
remains controversial because of the data showing RAI 
to be a risk factor of GO deterioration (according to the 
published data in 15–37% subjects) [3–6].
Clinically apparent orbitopathy is present in about 
30–40% of GD patients: there are severe changes in 5%, 
while 90% have subclinical eye disease revealed by MRI 
scan only. Currently, GCS cover is recommended after 
radioiodine administration to prevent GO worsening. 
The optimal way of administration, as well as the doses 
and time of treatment, remain open questions [7]. Most 
researchers agree that smoking is a serious risk factor 
influencing orbitopathy [8, 9]. Other suggested risk 
factors are: thyrotoxicosis at the time of RAI therapy, 
immunological activity of the disease reflected by high 
titres of serum TSH receptor antibodies, and post-
therapeutic hypothyroidism [10–14].
According to the current guidelines of the European 
Group on Graves’ Orbitopathy, the presence of GO is 
not considered as a contraindication for RAI treatment 
[15]. However, risk factors should be assessed individu-
ally and the patient must be informed about the pos-
sibility of GO exacerbation in order to give informed 
consent. In patients with mild GO, corticosteroid cover 
after RAI administration is recommended. In cases of 
moderate-to-severe GO, intravenous glucocorticoid 
therapy is the first line treatment and RAI therapy 
should be considered thoroughly in terms of the risk-
to-benefits ratio.
The aim of this study was a prospective evaluation 
of a GD patients cohort with different preexisting GO 
activity, focused on the risk of GO worsening after RAI 
treatment.
Material and methods
208 consecutive patients with Graves’ hyperthyroidism 
were treated with RAI between January and June 2007. 
Inclusion criteria were: former GD diagnosis, qualifica-
tion to RAI treatment, minimum age of 18 years, and 
consent for participation in the study. GO assessment 
was performed in the whole group. Patients with GO 
activity above CAS 3 and with constant diplopia were 
excluded from the study.
156 patients (127 women and 29 men) aged 18–79 
were enrolled. All patients were previously pharmaco-
logically treated due to hyperthyroidism, 11 patients 
underwent thyroid surgery before RAI treatment, 
whereas 26 were treated with radioiodine.
A strict follow-up was planned, with the first end-
point at 12 months after RAI administration. The initial 
examination was made by an endocrinologist, including 
biochemical evaluation of thyroid function, ultrasonog-
raphy (US) of thyroid gland, GO assessment based on 
CAS and NOSPECS scores. Previous ophthalmological 
symptoms, the presence of immunological diseases in 
a patient or his/her family and smoking history were 
also taken into consideration. Thyroid function and US 
as well as GO symptoms (using CAS/NOSPECS scores) 
were subsequently monitored by the endocrinologist 
at one, three, six and 12 months after RAI therapy. 
24-month follow-up was performed using the same 
protocol. Ophthalmological evaluation was performed 
by the same ophthalmologist (M.N.) in each patient 
between three and six months after RAI. In cases of 
GO exacerbation, the treatment was supervised by the 
ophthalmologist. 
Therapeutic radioiodine ionising energy dose was 
calculated according to the Marinelli formula with the 
goal of 150 Gy for the first treatment and 200 Gy in 
subjects previously radically treated (surgically or with 
radioiodine). Radioiodine activities ranged from 5 to 33 
mCi (mean 12.4 mCi).
GCS after RAI were administered in 72 (46%) 
subjects (56 patients with diagnosed orbitopathy and 
16 smokers without GO symptoms). Prednisone was 
administered (with initial oral dose 30 mg daily) start-
ing from the day of RAI therapy and then tapered off 
over three months. 
GO progression was evaluated as significant when 
CAS score deteriorated by at least 2 points or in the case 
of presence of new diplopia or exophtalmos, as well 
as when orbitopathy newly occurred. Intensity of GO 
symptoms was assessed during 12 months after RAI. 
Clinical follow-up was performed after 12 and 24 months 
(12 v. 0 and 24 v. 0, respectively) with evaluation of GO 
activity and advancement compared to the initial status. 
MRI of orbits was performed in 63/156 patients from 
the analysed group, among them in 56 patients before 
and 12 months after RAI treatment. 
The study project was approved by the institutional 
ethics review board.
Results
In the whole group (n = 156), there were 56 patients 
specified as the GO(+) group, comprising 39 patients 
with GO symptoms and 17 patients with positive 
42
PR
A
C
E 
O
RY
G
IN
A
LN
E
131I treatment in Graves’ orbitopathy  Aleksandra Król et al.
GO history without GO symptoms at the time of RAI 
therapy. 
In the remaining 100 patients without GO symp-
toms, the (GO(–) group), 16 smokers were categorised 
as an at risk group of GO exacerbation. 
GCS cover during RAI therapy were administered 
in GO patients and in no-GO smokers (Fig. 1).
During 12 months after RAI therapy, GO exacerba-
tion was observed in 29 patients from the whole group. 
In four of them with preexisting GO intravenous GCS 
were given 5–8 months after RAI therapy. In the remain-
ing 25 patients eye symptoms, classified as slight and 
transient, disappeared in the short term without any 
treatment or after using only moisturizing eye drops 
only (Fig. 2).
Transient GO worsening was stated in 10/39 patients 
with preexisting GO symptoms and in 6/16 patients 
with positive GO history; in total in 16/56 patients with 
GO symptoms or GO history — 29%. 
Moreover, transient progression was observed in 
9/100 patients (9%) from the GO(–) group — in eight 
non-smoker subjects and in one smoker. All these cases 
with mild worsening of GO symptoms were classified 
as newly diagnosed GO (Fig. 3). 
GO status was reassessed 12 and 24 months after 
RAI and compared to the initial examination. Clinical 
deterioration compared to the initial GO status was 
observed only in 3/156 subjects (2%) from the whole 
study group, whereas in 16/156 (10%) clinical improve-
ment was stated. In other patients, GO symptoms did 
not differ significantly before and after RAI therapy. 
Two years after RAI therapy (138 patients controlled), 
four cases of deterioration were diagnosed. These pa-
tients were only carefully monitored without systemic 
GCS treatment. There were 15 cases of improvement 
compared to the initial status (Fig 4.).
There were 39 patients with GO symptoms in the 
whole study group (n = 156) before RAI treatment 
(25%), among them ten GO patients with CAS 3, while 
one year after RAI therapy there were 33 symptomatic 
GO patients (21%) with two patients with CAS 3. Two 
years after RAI (n = 138) CAS 3 points was present in 
two of 22 symptomatic GO cases (16%) without any 
treatment required at that time (Fig. 5).
In the analysed group, 63 MRI examinations of orbits 
were performed before RAI. Only three MRI results 
were normal, whereas ten showed radiological features 
of active GO. In the remaining 50 cases, MRI confirmed 
inactive chronic GO or only minimal changes (different 
degrees of exophtalmos or signal abnormalities in eye 
muscles). To sum up, radiological GO features were 
present in 60/63 MRI. 
Figure 1. GO status estimated by CAS at the time of RAI therapy 
in the study group (n = 156). 84 patients without GO and non-
smokers were given RAI without GCS cover, while 16 pts without 
GO who were defined as smokers received RAI under GCS cover. 
In total, 72 pts received GCS and 84 did not receive any GCS cover
Rycina 1. Obecność i nasilenie objawów orbitopatii w oparciu 
o CAS w chwili leczenia 131I w grupie badanej (n = 156). 
U 84 chorych bez objawów orbitopatii i u niepalących tytoniu nie 
stosowano steroidoterapii, natomiast u 16 chorych-palaczy bez 
orbitopatii włączono osłonę steroidową
Figure 2. GO dynamic in the whole study group during 12 months 
of follow-up after RAI. Some pts (16%) showed only transient 
progression of GO, which did not demand GCS treatment
Rycina 2. Dynamika objawów orbitopatii w całej grupie badanej 
w ciągu 12-miesięcznego okresu obserwacji po leczeniu 131I. 
U części chorych (16%) obserwowano jedynie przejściową 
progresję, która nie wymagała stosowania glikokortykosteroidów
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Figure 3. GO severe and transient progression during the 12-month follow-up regarding initial GO presence. Only 10% of patients 
in the clinically apparent GO symptoms group progressed after RAI therapy despite GCS cover
Rycina 3. Ciężka i przejściowa progresja orbitopatii w ciągu 12-miesięcznego okresu obserwacji w zależności od stanu wyjściowego. 
Jedynie u 10 % chorych z objawową orbitopatią doszło do progresji po leczeniu 131I, mimo osłony steroidowej
Figure 4. GO worsening/improvement 12 (left) and 24 (right) months after RAI treatment compared to the initial GO status at RAI 
administration. Most GO patients showed stable GO as estimated 12 months and 24 months after treatment. Only in 3/156 patients had GO 
status deteriorated 12 months after RAI: these were all pts without GO symptoms at the time of RAI. In 4/138 patients, GO status was worse 
after 24 months than at the time of RAI: these were three patients with an initial history of GO and one with mild GO at the time of RAI 
Rycina 4. Pogorszenie/poprawa objawów orbitopatii 12 (lewy diagram) i 24 (prawy diagram) miesiące po leczeniu 131I w stosunku do stanu 
wyjściowego w chwili leczenia 131I. Większość chorych prezentowała stabilny stan orbitopatii po 12 i 24 miesiącach od leczenia. Tylko u 3/156 
pacjentów stan orbitopatii uległ pogorszeniu po 12 miesiącach od terapii 131I, byli to chorzy wyjściowo bez objawów orbitopatii. U 4/138 
chorych stan był gorszy po 24 miesiącach od leczenia 131I, w tym 3 chorych bez wyjściowo obecnej orbitopatii i jednego z łagodną orbitopatią
In 56 patients, MRI was performed twice — before 
and 12 months after 131-I treatment. In 11/56 (20%) 
cases, improvement was shown (reduction of exoph-
talmos, decrease of muscle thickness and change in 
muscle MRI appearance), whereas in 42/56 (75%) stable 
disease was diagnosed (there were no significant dif-
ferences between two MRI examinations) and in 2/56 
(3.6%) — worsening (increase of exophtalmos and 
thickening of eye muscles with signal change). One of 
the MRI examinations performed 12 months after RAI 
therapy was inconclusive because maxillary cancer 
was diagnosed and GO status was difficult to estimate.
Discussion
RAI treatment of hyperthyroidism in GD patients may 
be related to the risk of GO exacerbation — 15–37% ac-
cording to the published data [3, 4]. However, the exact 
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Figure 5. GO status in the study group at the time of RAI and 24 months after RAI. As evaluated 24 months after RAI treatment, 
patients of the study group showed significant improvement of GO when RAI treatment was performed with adequate GCS cover 
Rycina 5. Występowanie objawów orbitopatii w grupie badanej w chwili leczenia 131I oraz 24 miesiące po terapii. 24 miesiące po terapii 
obserwowano znaczącą poprawę w zakresie nasilenia orbitopatii, jeżeli terapię 131I przeprowadzono w osłonie steroidowej
evaluation of progression risk is difficult because most 
studies are nonrandomised, uncontrolled or retrospec-
tive. Moreover, ophthalmological examination is based 
on non-standardised evaluation of ocular changes. So, 
a comparison between subsequent assessments is dif-
ficult or even impossible. 
To properly assess the exacerbation of GO symptoms 
after RAI treatment, the natural course of the disease 
should be taken into consideration. Perros et al. dem-
onstrated that 13.5% (8/59) of patients deteriorated 
progressively during a 12-month follow-up to the extent 
that immunosuppressive treatment was considered to 
be necessary. Simultaneously, a natural improvement 
was observed in more than 64% of subjects [16]. The 
results of our study confirm this observation. 
It is widely known that RAI treatment is more risky 
than surgery or pharmacotherapy as far as GO is con-
cerned. So, according to some authors, surgical methods 
seem to be the treatment of choice [17, 18]. According 
to other authors, the risk of GO exacerbation after RAI 
treatment is minimal, especially under GCS cover ad-
ministration [19] and we have proven this view in our 
study. Efficacy as well as schema of GCS prophylaxis 
is still under discussion [20–22]. 
In the present study, we assumed that if GO pro-
gression occurred within one year after 131I treatment, 
it was most probably due to the 131I administration. 
Separate analysis was carried out for severe GO pro-
gression demanding GCS treatment and for transient 
worsening without any treatment needed. The risk of 
GO progression during the 12-month follow-up and 
final treatment outcomes (GO status 12 and 24 months 
after RAI) were analysed separately. Moreover, strict 
criteria of GO progression during the first year, as well 
as improvement criteria after one and two years based 
on CAS and NOSPECS scores, were established.
This study has been planned on the basis of our 
own retrospective analysis (not published), which 
involved 299 GD patients treated with RAI in 2006 
(among them 103 with overt GO in whom GCS cover 
was administered) with at least 12 months of follow-up. 
GO progression was observed in 7/103 (6.8%) and only 
four of them needed GCS therapy. The differences in 
progression rate compared to the present prospective 
study may be due to the fact that some mild and tran-
sient GO exacerbations could be lost in the retrospective 
observation.
In this prospective study, patients with various 
stages of GO were qualified to 131I treatment, among 
them subjects with active GO, GD patients without 
any clinical GO features but with positive GO history, 
as well as patients without any GO symptoms.
Our findings are similar to the published data 
concerning the frequency of MRI ophthalmological 
symptoms in GD patients (taking into account also 
subclinical cases) which show that almost every GD 
patient must be considered as a potential GO subject. 
MRI is not usually necessary, only in doubtful cases, 
hence the assessment of the patients and qualification 
for GCS prophylaxis were based on physical examina-
tion, according to the widely accepted criteria. GCS 
coverage was used according to the current EUGOGO 
guidelines. Clinical and MRI evaluation after one 
and two years confirmed GO improvement in most 
patients. The rate of deterioration one year after 131I 
administration was not higher as in the natural course 
of GO. However, the question of how to treat patients 
with active GO remains open and encourages further 
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prospective studies based on strict ophthalmological 
criteria involving a large number of patients [23, 24].
Conclusions
1. The risk of GO induction in GD patients without any 
GO symptoms or with subclinical GO manifestation 
(diagnosed by MRI) is minimal.
2. We conclude that RAI treatment of GD hyperthy-
roidism constitutes a safe therapeutic tool in GD 
patients with mild GO. 
3. Distant outcomes of treatment are positive. Clinical 
improvement confirmed by MRI was stated in most 
patients one year and two years after RAI.
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